Xilio Therapeutics
35 hedge funds and large institutions have $24.7M invested in Xilio Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
1,788% more capital inflows, than outflows
Capital inflows: $11.8M | Capital outflows: $627K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
20.25% more ownership
Funds ownership: 36.3% → 56.55% (+20%)
6% more funds holding
Funds holding: 33 → 35 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$230K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$69.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$48.2K |
| 4 |
Aptus Capital Advisors
Fairhope,
Alabama
|
+$40.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$39.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$512K |
| 2 |
Two Sigma Securities
New York
|
-$35K |
| 3 |
Engineers Gate Manager
New York
|
-$25.8K |
| 4 |
Millennium Management
New York
|
-$16.3K |
| 5 |
Avantax Planning Partners
Dubuque,
Iowa
|
-$16.1K |
XLO Hedge Fund Activity: Q4 2024 in Review
35 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2024, worth a combined $24.7M — up 96% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XLO positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was UBS Group, adding an estimated $230K. The largest seller was Morgan Stanley, cutting an estimated $512K.
- 35 institutional investors held Xilio Therapeutics (XLO) as of Q4 2024, up from 33 in Q3 2024.
- Funds reported $24.7M of Xilio Therapeutics stock for Q4 2024, up 96% quarter-over-quarter.
- 9 funds opened new Xilio Therapeutics positions in Q4 2024 and 5 closed out, a net change of +4 holders.
- The largest Xilio Therapeutics buyer in Q4 2024 was UBS Group, an estimated $230K added.
- The largest Xilio Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $512K sold.
Based on aggregated 13F filings for Q4 2024.